A combination of two drugs - one of them an immunotherapy agent - could become a new standard, first-line treatment for patients with metastatic kidney cancer, results from a phase 3 clinical trial show. 'Hopefully this will lead to Food and Drug Administration approval soon,' says lead researcher.

See the source article by following the link below:
A combination of two drugs - one of them an immunotherapy agent - could become a new standard, first-line treatment for patients with metastatic kidney cancer, results from a phase 3 clinical trial show. 'Hopefully this will lead to Food and Drug Administration approval soon,' says lead researcher.